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INTRODUCTION
In this series of papers, we have described a selection of statistical
methods used for the initial analysis of survival time data (Clark
et al, 2003), and introduced a selection of more advanced methods
to deal with the situation where several factors impact on the
survival process (Bradburn et al, 2003). The latter paper focused
on proportional hazards (PH) and accelerated failure time (AFT)
models, and we continue the series by demonstrating the
application of these models in more detail. Whereas the focus of
the previous paper was to outline the purpose and interpretation of
statistical models for survival analysis, we concentrate here on
approaches with which to undertake the actual modelling process.
In other words, the aim of this paper is to promote the correct use
of the models that have been suggested for the analysis of survival
data.
When used inappropriately, statistical models may give rise to
misleading conclusions. Checking that a given model is an
appropriate representation of the data is therefore an important
step. Unfortunately, this is a complicated exercise, and one that has
formed the subject of entire books. Here, we aim to present an
overview of some of the major issues involved, and to provide
general guidance when developing and applying a statistical
model. We start by presenting approaches that can be used to
ensure that the correct factors have been chosen. Following this,
we describe some approaches that will help decide whether the
statistical model adequately reflects the survivor patterns ob-
served. Lastly, we describe methods to establish the validity of any
assumptions the modelling process makes. We will illustrate each
using the two example datasets (a lung cancer trial and an ovarian
cancer dataset) that were introduced in the previous papers
(Bradburn et al, 2003; Clark et al, 2003).
CHOICE OF COVARIATES
The covariates that we consider here are fixed, that is, known at
baseline or entry to the study. The handling of covariates that
change values over time (e.g. white blood cell count as measured at
different time points) will be described in the subsequent paper in
this series.
Sample size considerations
It is implicitly assumed that the subjects in a study are
representative of a wider population to enable the study aims to
be addressed. Another important requirement is to have data from
an adequate number of subjects. Any estimate based on a small
number of individuals will be less reliable than one based on a
larger number, and when multivariate models are fitted to small
datasets, the estimated impact of the covariates is too imprecise to
give reliable answers. The use of variable selection procedures as
described below is especially problematic with such data, and often
leads to overoptimistic results. Finally, smaller data sets may not
have sufficient power to detect a covariate that has a significant
impact on survival.
The power (and indeed in some cases validity) of a survival
analysis is related to the number of events rather than the number
of participants. Simulation work has suggested that at least 10
events need to be observed for each covariate considered, and
anything less will lead to problems, for example, the regression
coefficients become biased (Peduzzi et al, 1995). In the ovarian
study, there were 550 deaths and 11 covariates for the five
prognostic factors, implying 50 events per covariate. In the liver
cancer trial with 114 events, a full model of 11 covariates has
approximately 10 events per covariate.
For prospective studies, several books (e.g. Machin et al, 1998)
and software packages (e.g. nQuery, power and precision) are
available to assist the calculation of adequate sample sizes, and
many general purpose statistical packages also perform such
calculations.
The aim of the study influences the choice of covariates
Before embarking on any statistical modelling, it is helpful to be
clear as to why the multivariate model is to be fitted. The models
we have presented have the considerable advantage of being able to
handle several factors simultaneously, but the choice of which to
incorporate lies with the analyst. This choice depends on the study
aims. We suggest three possible scenarios as to why a study may
use a multivariate model, and deal with each in turn.
(a) A single factor is under investigation for its association with
survival, but several other factors exist
The rationale of such a study is to perform a specific test of one
factor. This scenario may arise in a randomised controlled trial,
such as the lung cancer example, where the aim is to decideReceived 6 December 2002; accepted 30 April 2003
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whether a new treatment prolongs survival, but also to adjust for
prognostic factors that may or may not be equally matched
between treatment groups. Another situation occurs where an
association between a marker and patient survival is being
assessed. In either case, any terms that are of potential importance
could be incorporated whether significant or not, depending on
the adequacy of the sample size. All of the covariates (other than
the one of primary interest) are essentially ‘nuisance’ factors that
are considered only to ensure they have been taken due account
for in assessing the importance of the (prespecified) factor under
investigation. Less important covariates may be removed.
(b) A collection of factors of known relevance are under
investigation for their ability to predict survival
This arises when one wishes to assess the individual importance of
a series of factors, and/or to attempt to build a model that helps
predict patient survival. In such cases, the simplest strategy is to
attempt to model all covariates, obtain effect sizes and gauge how
well the model predicts survival. It may be desirable to remove
factors from the model for simplicity, provided this does not
compromise the predictive ability of the model. Statistical
significance alone is an insufficient measure of assessing the
extent to which a covariate can predict survival. Methods that may
be used for this evaluation are given in the final paper of this
series.
(c) Where a collection of factors are under investigation for their
potential association with survival, possibly with additional known
factors
Such studies are more ‘exploratory’ in nature, and the aim is to
identify quantities of potential importance for further investiga-
tion. Here it is often desired to reduce the number of covariates in
the model by excluding those that are not statistically significant
and thus concentrate only on ‘potentially interesting’ ones for
future research. Care must be exercised when several covariates are
investigated, as the false-positive rate (or the chance of finding a
spurious effect) increases with each additional test.
This selection of scenarios is far from exhaustive, and in practice
a study may combine all of the above types. The ovarian study is a
combination of (b) and (c).
Approaches to adding or removing covariates
Common choices for model building focus on ‘semiautomated’
methods such as stepwise selection, but other approaches exist.
Models that are based purely on statistical significance may not be
clinically meaningful. Henderson and Velleman (1981) state this
simply: ‘The data analyst knows more than the computer’, and
appropriate use of this knowledge should be incorporated into the
analysis. We recommend that the choice of covariates should be
verified by a degree of hands-on modelling, where terms are added
or removed in a logical order rather than solely according to
statistical significance.
We illustrate some straightforward approaches to the choice of
covariates in the two example datasets used in this paper. In the
final paper of this series, we will outline the rationale behind
semiautomated methods (together with their limitations) and give
further advice on hands-on modelling.
Selecting covariates for the lung cancer trial
As stated before, the lung cancer trial as presented in the earlier
paper is an example of scenario (a). The table of coefficients for the
full AFT multivariate model was presented in the previous paper
(Bradburn et al, 2003). A simpler model would be to consider just
the performance status, cell type and treatment covariates.
Removing the remaining covariates reduces the model likelihood,
but not to a significant degree (w2¼ 3.34 on 8 degrees of freedom;
P¼ 0.91). The new time ratios, confidence intervals and P-values
are presented in Table 1. They are virtually unchanged from the
previous analysis, and thus the earlier conclusions remain the
same.
Selecting covariates for the ovarian cancer database
As stated previously, the analysis of the ovarian cancer database
(as described in the previous paper) could be considered as a
mixture of scenarios (b) and (c). However, as the database is large
and the aim is to derive a prognostic model, we will focus on (b).
We consider five covariates here, all of which were measured at
diagnosis: FIGO stage (an ordinal covariate taking values 1, 2, 3 or
4), histology (with seven possible subtypes), grade, ascites (yes/no)
and patient age.
In this analysis, all the covariates were included yielding the
model presented in Table 2. Advanced FIGO stage, higher grade,
presence of ascites and increased age all impaired survival to
varying degrees. The mucinous and serous histology types had a
better prognosis, and undifferentiated and mixed mesodermal a
lesser one. No grade –histology interactions were included in the
final model, either due to insufficient numbers of patients to allow
meaningful modelling (e.g. clear cell, mixed mesodermal, adeno-
carcinoma or undifferentiated), or for statistical insignificance (the
remainder). In fact no second-order interaction or nonlinearity
was detected.
If this model were to be used for the purpose of predicting
future survival patterns, it is appropriate to ensure that the effect
sizes are robust. One approach is to use bootstrap sampling, which
involves randomly resampling the data and fitting the model to
these modified datasets (Clark and Altman, 2002). These produce a
series of effect sizes that should be similar to those derived from
the original data if the model is sufficiently stable, and indeed do
so here.
ASSESSING THE ADEQUACY OF A MODEL
Regardless of which type of model is fitted and how the variables
are selected to be in the model, it is important to evaluate how well
the model represents the data. A survival model is adequate if it
Table 1 Generalised gamma AFT model applied to the lung cancer data
Covariate Coefficient (bi) TR [exp(bi)] 95% CI P-value
Treatment (RT+CAP vs RT alone) 0.640 1.90 (1.23–2.93) 0.004
Cell type (squamous vs nonsquamous) 0.536 1.71 (1.08–2.71) 0.02
Performance status (8–10 vs 5–7) 0.765 2.15 (1.09–4.24) 0.03
TR¼ time ratio; CI¼ confidence Interval; RT¼ radiotherapy; CAP¼ cytoxan, doxorubicin and platinum-based chemotherapy.
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represents the survival patterns in the data to an acceptable degree.
This aspect of a model is known as goodness of fit. For example, if a
given group of patients have a poor (or good) prognosis, then the
model should predict this group to have that outcome. In practice,
the issues in choosing the most appropriate type of model and the
most appropriate covariates are heavily related, and the adequacy
of a model may be assessed in several ways. In this section, we
discuss methods to verify fit that are common across all survival
models, before describing approaches specific to different model
types. We will use the ovarian database example to demonstrate
these checks.
Residuals from survival models
Residuals are a useful method for checking the fit of a statistical
model. Essentially, they are the difference between an observed
and a model-predicted quantity, with large or systematic
differences between the two indicative of a poor model. Several
residuals have been proposed, but unfortunately most are rather
difficult to understand in the context of survival analyses due to
censoring (Collett, 1994). In general, the residuals are skewed and
need to have smoothing functions (e.g. Kernel smoother) applied
to aid interpretation. Nevertheless, the graphical displays sug-
gested in Table 3 (with appropriate smoothing as required) should
all give rise to an evenly scattered horizontal band and display no
obvious trend (e.g. no slope). If a trend in these plots is apparent, it
should be investigated, perhaps using the method suggested in
Table 3. Overall model adequacy may be assessed by use of Cox-
Snell residuals (Collett, 1994).
Residual plots for the ovarian cancer data set
Figures 1A illustrates a plot of the Martingale residuals against the
patient’s age, with a Kernel smoother marked as the dashed line.
Figure 1B shows the Martingale residuals plotted against FIGO
stage, with the median within each stage represented by the solid
bar. Both FIGO and age were modelled as linear effects. If FIGO or
age had been wrongly excluded or modelled incorrectly (i.e.
nonlinear), the figures should display a trend other than a strictly
horizontal line. The age residual plot shows no evidence of a trend.
Although there appears to be evidence of a trend in the FIGO plot,
the inclusion of this covariate as a categorical covariate fails to
Table 2 Cox model applied to the ovarian data
Covariate Coefficient (bi) HR [exp(bi)] 95% CI P-value
FIGO stage 0.731 2.08 (1.82–2.37) o0.001
Histology o0.001
Serous (0.000) (1.00)
Mucinous 0.422 0.66 (0.50–0.85)
Endometroid 0.198 1.22 (0.80–1.85)
Clear cell 0.342 1.41 (0.99–2.00)
Adenocarcinoma 0.501 1.65 (0.91–2.99)
Undifferentiated 0.746 2.11 (1.03–4.29)
Mixed mesodermal 0.789 2.20 (1.45–3.35)
Grade o0.001
1 (0.000) (1.00)
2 0.885 2.42 (1.40–4.19)
3 0.885 2.42 (1.40–4.18)
Absence of ascites 0.396 0.67 (0.54–0.84) o0.001
Age (per 5-year increase) 0.133 1.14 (1.09–1.19) o0.001
HR¼ hazard ratio; CI¼ confidence interval.
Table 3 Suggested plots for residual-based diagnostics
Y-axis X-axis Potential implication Suggested remedy
Martingale residual Any omitted covariate Covariate excluded
wrongly
Refit model with covariate included
Martingale residual Any included covariate Covariate modelled
incorrectly
(e.g. nonlinear effect)
Fit nonlinear term (e.g. a squared term)
Martingale residual Date of enrolment in study Evidence of temporal effect Incorporate time of entry as a covariate
Deviance residual Survival time, log(survival time)
or ranks of survival time
Model fails to predict
consistently for
all survival times
Fit time-dependent PH model or consider using a different
(i.e. non-PH) model
Deviance residual Subject identifier Individual is an outlier (1) Check if the data are correct
(2) Refit model with individual removed. If effect sizes alter
substantially, consider removing individual altogether
Scaled Schoenfeld
residual
Survival time, log(survival time)
or ranks of survival time
Non-PH Fit time-dependent PH model or consider using a different
(i.e. non-PH) model
PH¼ proportional hazards. All of the above X–Y plots should give rise to a plot evenly scattered along a horizontal line that displays no trend. The possible implications where
this does not occur and suggested remedies are presented.
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improve the fit to a significant degree. Thus, we may be reasonably
confident that the model is adequate for both covariates.
Identifying the correct parametric model
When fitting a fully parametric model, the survival times are
assumed to follow a statistical distribution. Several different
distributions have been proposed, and the identification of a
suitable one is a crucial step. The most obvious distinguishing
feature between parametric models is in the shape of the hazard
they assume the data follow. The Weibull and Gompertz
distributions are appropriate when the hazard is always increasing
or decreasing; the Log-Logistic may be used where the hazard
either rises to a peak and then decreases or always decreases; the
Log-Normal and Generalised Gamma models are preferable when
the hazard rises to a peak before decreasing. In the Exponential
model, the hazard is assumed to be constant over time. The actual
shapes of these distributions (e.g. the point in time at which a
hazard ‘peaks’ or the gradient at which it increases/decreases)
depend on ancillary parameters that are also estimated from the
data. For example, when using the Weibull distribution, the hazard
function, h(t), is ls(lt)s1. In this case, the shape (s) and scale (l)
parameters are the ancillary parameters to be estimated (see
Figure 1 in the previous paper Bradburn et al, 2003).
If the shape of the disease hazard is known to be different from
that of a particular distribution, then the data should not be
analysed with this parametric model. For example, consider the
hazard for overall survival after cancer diagnosis. The hazard is
rarely constant, thus ruling out an Exponential distribution. In
some cases, the hazard rises sharply (due to treatment deaths)
before tailing off, which would also rule out the Weibull. An
informal assessment of a parametric model’s appropriateness may
be made via plotting the (smoothed) empirical hazard or
cumulative hazard against those estimated by the model, or by
log(log(survival)) plots which are discussed later. Akaike’s
Information Criterion (AIC) (Akaike, 1974), a statistic that trades
off a model’s likelihood against its complexity, may also be used
when comparing the viability of different parametric models. The
AIC of a model may be defined as
AIC ¼ 2LL þ 2ðc þ aÞ
where LL is the logarithm of the model likelihood (log-likelihood),
c is the number of covariates and s the number of ancillary
parameters (e.g. 2 in the case of the Weibull; l and s). A lower
value of the AIC suggests a better model. Note, however, that the
likelihood computed in a Cox model is a partial likelihood, and so
it is not possible to compare Cox PH models to fully parametric
ones in this manner.
In the PH framework, it may be clear that none of the parametric
models suggested here or elsewhere adequately capture the
distributional form of the data. In such cases, the more flexible
Cox model is the obvious choice. Commonly used parametric
models in the AFT framework are arguably more flexible than
those available in the PH framework, and so fitting a parametric
AFT model is another option.
Overall goodness-of-fit tests
A simple test for the model adequacy is to compare the overall
(Kaplan– Meier) survival curve to the model-based predicted
survival and, ideally, for any group of patients the two should be
close, if not identical. Hosmer and Lemeshow (1999) suggest using
a more formal measure of fit based on comparing observed and
expected events in different risk groups as defined by the model.
Specifically, the predicted risk or prognostic index (PI) from a
model consisting of covariates x1, x2, y, xp with estimated
coefficients b1, b2, y, bp, respectively, is
PI ¼ b1x1 þ b2x2 þ    þ bpxp
PI is calculated for each patient. Risk groups are constructed by
categorising the (ranked) PIs, for example, three risk groups can
be created using the highest, middle and lowest tertiles of PI. A
score test is then applied to the differences between the observed
and expected events in the risk groups. A simple approximation to
this calculation may be obtained by adding the risk groups as a
series of covariates to the survival model itself. A significant
improvement in the model likelihood suggests that the original
covariates form an insufficient model for the data.
Assessing overall goodness of fit on the ovarian cancer
data
The predicted survival curves for the ovarian cancer model are
potentially misleading. Several factors are associated with length of
survival, and some are also related to (or correlated with) each
other (e.g. histology and stage). Predicted survival curves for each
histological group may be estimated by fixing all other covariates
at their mean values. However, this approach will give an estimate
of survival that is different to those observed in the data because
correlations are ignored. The test of Hosmer and Lemeshow (1999)
is more useful here. The patients are split into ten risk groups, with
the proportion of deaths in each ranging from 10% in the best
prognosis group to 94% in the worst. The approximate score test,
derived from adding nine covariates to the model, produced no
evidence of a poor fit (likelihood ratio test w2¼ 7.84 on 9 degrees of
freedom, P¼ 0.55).
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Figure 1 Martingale residuals plotted against (A) patient age and (B)
FIGO stage; median for each stage is denoted by a horizontal line.
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ASSESSING WHETHER PH IS APPROPRIATE
The PH assumption, that is, the hazards are proportional (and not
overlapping) at all points in time, should be verified. An obvious
approach is to plot the hazard in each group, but this is of limited
use. The empirical hazard function is generally not well estimated,
and instead the cumulative hazard is generally preferred to assess
the PH assumption. If a PH model is valid, a plot of the logarithm
of the cumulative hazard function in each group against the
logarithm of time should give rise to lines that are parallel.
Continuous variables need to be categorised into groups. The plot
described is also known as the log(log(survival)) plot, as the
cumulative hazard is equal to the negative logarithm of the survival
proportion. This approach requires a subjective assessment.
Unfortunately, convergent or divergent lines may be due to either
a lack of proportionality or to the omission of an important
covariate. In practice, it is not known which, but this phenomenon
suggests an inadequate model. On the other hand, parallel lines
suggest that models assuming PHs may be suitable. In the case of
fitting a Weibull or an Exponential parametric model, the lines
should be parallel and straight.
Several formal statistical tests have been proposed for assess-
ment of proportionality of hazards. A simulation study by Ng’andu
(1997) described and compared several tests in the Cox PH
framework, and concluded that the (weighted) scaled Schoenfeld
residuals test (Grambsch and Therneau, 1994), the linear correla-
tion test (Harrell, 1986) and the time-dependent covariate test
(Cox, 1972) were the most powerful diagnostic tools for
proportionality. The first two of these test for an association
between residuals and time (evidence of which indicates a bad fit),
and the third tests whether the effect (coefficient) of a covariate
changes with time (i.e. nonconstant hazard ratio). This latter
method is appealing as it not only detects nonproportionality, but
allows it to be modelled validly. An alternative is to fit a stratified
model, wherein a covariate that displays nonproportionality is
modelled without the constraint of proportionality. Such a
covariate must obviously be categorical (or be categorised), but
more importantly has no estimated effect size provided when
forming the strata of a stratified model, and thus is suitable only
for covariates that are not of primary interest. Abandoning the PH
approach in favour of some other model is clearly another option.
Assessing the appropriateness of PH for the ovarian cancer
data
The Kaplan– Meier survival curves and log(log(survival)) vs
log(time) plots are shown for FIGO stage and histology in Figure
2A– D. The log(– log(survival)) plot for FIGO stage gave rise to
reasonably parallel lines and therefore suggests proportionality.
However, in the case of the histology, this appears to be violated.
In particular, the prognosis for the endometroid group sits in the
middle of all the groups in the first year but improves thereafter. A
similar feature was apparent for the presence of ascites, where the
initial detrimental effect becomes less important with time (data
not shown). The (weighted) scaled Schoenfeld residuals test
suggested significant overall nonproportionality (P¼ 0.05), as did
the time-dependent covariate tests for these terms. Therefore,
despite other aspects of this model appearing adequate, the
assumption of proportionality appears to be violated.
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Figure 2 (A) Survival according to FIGO stage. (B) Log(log(survival)) for FIGO stage. (c) Survival according to histology. (D) Log(log(survival)) for
histology. The endometroid group is shown by the dotted line.
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Nevertheless, we can still use a Cox PH model with time-
dependent covariates implemented, which is a model that includes
interaction terms between the covariates and (log) time, and thus
allows the effect of the relevant covariates to change with time.
Table 4 shows the amended model that now allows the effects to
vary with time. The time-dependent terms suggest that the absence
of ascites and endometroid histology have effects that diminish
(the hazard ratios tend towards 1) with time. For example, the
absence of ascites is judged to have a hazard ratio of
exp(0.466þ 0.233 log(2))¼ 0.74 at 2 years but exp(0.466þ
0.233 log(5))¼ 0.91 at 5 years.
ASSESSING WHETHER AN AFT MODEL IS ADEQUATE
In the AFT model, the survival proportion in one group at any
time t is equal to the survival proportion in the second at time jt,
where j is constant. Therefore, a Quantile–Quantile (Q– Q) plot of
the times of survival percentiles should lie on a straight line of
slope j that passes through (0, 0). As with the log(log(survival))
plot in PH models, this is a useful but limited approach as
departures from linearity could be due to the AFT model being
inappropriate or that one or more important covariates have been
omitted. The methods of stratification or modelling with time-
dependent covariates suggested in the PH section may be applied
here as well.
The lung cancer trial data
We assessed the adequacy of the Generalised Gamma and four
other parametric models (each with all covariates included) and
present their AIC values in Table 5. The Generalised Gamma model
has a higher log-likelihood than the other models and a lower AIC,
indicating that this distribution may be the most accurate. To
check for excluded covariates, the Martingale residuals were
plotted against potential model terms as before. None of these
plots suggested that a covariate was incorrectly omitted. Figure 3
Table 4 The Cox model applied to the ovarian data, with a time dependency added to ascites and
endometroid terms
Covariate Coefficient (bi) HR [exp(bi)] 95% CI P-value
FIGO 0.734 2.09 (1.83–2.38) o0.001
Histology o0.001
Serous (0.000) (1.00)
Mucinous 0.432 0.65 (0.50–0.85)
Clear cell 0.344 1.41 (0.99–2.01)
Adenocarcinoma 0.494 1.64 (0.91–2.96)
Undifferentiated 0.769 2.16 (1.06–4.40)
Mixed mesodermal 0.825 2.28 (1.50–3.47)
Endometroid 0.312 1.37 (0.90–2.07)
Endometroid log(time) 0.500 0.61 (0.45–0.82) 0.001
Grade o0.001
1 (0.000) (1.00)
2 0.826 2.28 (1.32–3.95)
3 0.843 2.32 (1.35–4.00)
Absence of ascites 0.466 0.63 (0.50–0.80) o0.001
Ascites log(time) 0.233 1.26 (1.01–1.58) 0.04
Age (per 5-year increase) 0.134 1.14 (1.09–1.20) o0.001
HR¼ hazard ratio; CI¼ confidence interval.
Table 5 Akaike Information Criterion (AIC) of five different distributions fitted to the full model
Model Log likelihood (LL) No. of covariates (c) No. of ancillary parameters (a) AIC
Exponential 259.28 11 1 542.55
Weibull 253.21 11 2 532.41
Log-Normal 238.22 11 2 502.44
Log-Logistic 236.33 11 2 498.65
Generalised Gamma 235.79 11 3 499.58
AIC¼2LL+2(c+a).
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Figure 3 Kaplan–Meier survival probabilities for patients treated by
RTþCAP (solid line) and RT alone (dashed line). The respective predicted
survival proportions of a generalised gamma multivariate model are given
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CAP¼ cytoxan, doxorubicin and platinum-based chemotherapy.
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gives the predicted observed survival curves together with the
predicted survival under a Generalised Gamma model; for each
treatment group, the Karnofsky performance status and cell type
were fixed at their mean values. The medium-term survival is not
as well fitted by the model but is tolerably close. The long-term
survival is also less well estimated, but because few patients survive
this length of time the estimated survival is imprecise and so this
does not cause grounds for concern. The survival times for the
10th, 20th, y, 90th survival percentiles for each treatment group
are plotted as a Q–Q plot in Figure 4 and, again, apart from the
later times seem to fit adequately.
DISCUSSION
This paper has sought to demonstrate the models introduced in the
previous paper in this series (Bradburn et al, 2003), to offer
practical advice on how to select a method that represents the data
fairly, and how to present and interpret it. Good modelling of
survival data is not a straightforward exercise, and it is not
possible to suggest an ‘off the peg’ solution. Before starting the
process of deciding which (if any) of the models suggested is most
suitable for an individual dataset, the important question of why
the model should be fitted needs to be considered. The answer
should inform the modelling process. Although it is possible to
choose a model from those suggested that is optimal from a purely
statistical point of view (e.g. goodness-of-fit measures), nonstatis-
tical considerations should to be taken into account. The choice of
model and of covariates therein should, in general, be suggested
from experience and based on the specific question under
investigation. However, good nonstatistical reasons informing
model choice should not override good statistical reasons for not
choosing that model. The diagnostics (e.g. residuals) for the
different models may be difficult to interpret, but they will give an
indication of whether modelling assumptions hold and, ultimately,
should be considered when model building.
In some cases, all of the models mentioned above may not
be wholly appropriate either for modelling the data or ans-
wering the relevant question. Consider an example where the
time between treatment and possible multiple cancer relapse is
to be investigated. The methods introduced assume one survival
time (culminating in one type of event), but we may be
dealing with patients who have one or more relapses of different
type or levels. In the final paper of this series, we introduce models
that extend the types of models described here to incorporate
recurrent events. We also present approaches to modelling
continuous covariates in a nonlinear fashion, validating models
and discuss alternatives when fundamental censoring assumptions
do not hold.
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Figure 4 Q–Q plot (percentiles of survival distribution) for patients
RTþCAP against those with RT only. The plot symbols are the survival
percentiles* and the slope corresponds to the value of the time ratio
(¼ 1/1.90). * The 10th percentile is omitted: 4.9 and 11.4 years for RT
and RTþCAP respectively, RT¼ radiotherapy, CAP¼ cytoxan, doxor-
ubicin and platinum-based chemotherapy.
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